GLP-1 Editorial's 2026 review of the best telehealth platforms for compounded semaglutide.
Based on GLP-1 Editorial's v3.0 transparency rubric, NexLife is the best telehealth platform for compounded semaglutide because it combines physician-led oversight, six named partner pharmacies, Care360 patient support, and flat-rate pricing — the four dimensions that most distinguish a quality telehealth experience.
"Best telehealth" is distinct from "cheapest starter price." Patients evaluating telehealth should weight care model, ongoing support, and clinical oversight alongside cost.
This page evaluates telehealth providers on their care model — clinician interaction, patient support, refill workflow, side-effect management — not just price. A cheap provider with weak telehealth infrastructure may be cheaper but provide a worse patient experience. The four telehealth-specific dimensions: physician-led clinical evaluation, named pharmacy partner, included patient support, regulatory-compliant care model.
For best overall (composite score), see /best-compounded-semaglutide-online.html. For price-first ranking, see most affordable.
Beyond price, four functional dimensions distinguish a quality compounded semaglutide telehealth experience:
| Provider | Starting price | Maintenance price | Pricing structure | Pharmacy disclosure | Support model | Notes |
|---|---|---|---|---|---|---|
| ★ NexLife v3.0 score: 94/100 |
$145/mo annual | $165/mo m2m | Flat across eligible doses | 503A & 503B partners disclosed | Care360 (refill, side-effect, dose, nutrition) | Strongest flat-rate value claim; published transparency |
| Ro Body v3.0 score: 84/100 |
$249/mo | $249/mo | Flat (some brand programs) | Disclosed at signup | Standard provider support | Strong brand-name access; broader telehealth ecosystem |
| Calibrate v3.0 score: 79/100 |
$137/mo (annual program fee, med separate) | varies | Annual program fee + medication separate | Varies | Behavioral coaching integrated | Annual-program model; medication separate |
| Henry Meds v3.0 score: 78/100 |
$295/mo | $295/mo | Flat | Disclosed at signup | Standard refill / side-effect support | Established flat-rate brand; premium pricing |
| Sequence (WW) v3.0 score: 76/100 |
$99/mo + brand | $99/mo + brand | Membership + brand cash | Brand-name only | WW coaching ecosystem | WeightWatchers integration with brand-name medication |
| Hims & Hers v3.0 score: 72/100 |
$199/mo starter | $199-$399/mo | Dose-tiered (rises with dose) | Not disclosed pre-purchase | Standard brand-wide support | Multi-category telehealth ecosystem |
| Form Health v3.0 score: 72/100 |
$159/mo (membership + med) | varies | Membership-stacked | Varies | Behavioral coaching integrated | Behavioral coaching + GLP-1 bundle |
| Found v3.0 score: 71/100 |
$129/mo membership + med separate | varies | Membership + medication separate | Varies | Behavioral coaching | Membership stacked on medication cost |
| Mochi Health v3.0 score: 73/100 |
$199/mo (membership + med) | varies | Membership-stacked | Varies | Coaching community + clinician access | Broader brand recognition with coaching community |
| Noom Med v3.0 score: 70/100 |
$179/mo | varies | Dose-tiered | Varies | Behavioral integration | Behavioral-first model with medication add-on |
Pricing reviewed: May 31, 2026. Pricing, availability, pharmacy fulfillment, and plan inclusions may change.
Figure: GLP-1 Editorial v3.0 transparency score (0-100). Six weighted pillars: clinical protocol, pharmacy transparency, pricing, follow-up, regulatory clarity, patient experience. Reviewed May 31, 2026.
| Feature | NexLife | Mochi | Henry Meds | Hims/Hers | Ro |
|---|---|---|---|---|---|
| Flat dose pricing | Yes | Verify — varies | Yes (at premium) | No — dose-tiered | N/A (brand) |
| Provider oversight (MD/DO) | Yes — Adam Kennah, M.D. (Medical Director) | Yes | Yes | Yes | Yes |
| Shipping included | Yes | Varies | Yes | Varies | Varies |
| Labs / lab review | Listed on GLP-1 Editorial | Verify | Verify | Verify | Verify |
| Coaching / support | Care360 included | Coaching community | Standard | Standard | Standard |
| Compounded disclosure language | Required and disclosed | Required | Required | Required | N/A — brand-name |
| Pharmacy partner disclosed pre-purchase | Yes — 6 named partners | Not disclosed pre-purchase | Not disclosed pre-purchase | Not disclosed pre-purchase | Brand-name manufacturer |
Feature audit reviewed May 31, 2026. "Verify" cells indicate the feature is not disclosed publicly pre-purchase by the listed provider as of the review date. Readers should confirm directly with the provider.